Article Text

Download PDFPDF

LP-191 Baseline profile of systemic lupus erythematosus patients on treatment with belimumab of a Spanish multicenter cohort
  1. Irene Altabás-González1,19,
  2. José María Pego-Reigosa1,19,
  3. Coral Mouriño-Rodriguez1,19,
  4. Norman Jiménez-Otero1,19,
  5. Andrea Hernández-Martín2,
  6. Judit Font-Urgelles3,
  7. Ivette Casafont-Sole3,
  8. José Andrés Roman-Ivorra4,
  9. Marta De La Rubia-Navarro4,
  10. María Galindo-Izquierdo5,
  11. Tarek Salman-Montes6,
  12. Javier Narváez7,
  13. Paola Vidal-Montal7,
  14. María Jesús García-Villanueva8,
  15. Sandra Garrote-Corral8,
  16. María Ángeles Blázquez-Cañamero8,
  17. Carlos Marras-Fernández9,
  18. María Piqueras-García9,
  19. Julia Martínez-Barrio10,
  20. Marina Sánchez-Lucas10,
  21. Josefina Cortés-Hernández11,
  22. Eleonora Penzo11,
  23. Jaime Calvo-Alen12,
  24. Juan Ramón De Dios Jiménez De Aberásturi12,
  25. Belén Álvarez-Rodríguez12,
  26. Margarida Vasques-Rocha12,
  27. Eva Tomero13,
  28. Raúl Menor-Almagro14,
  29. Myriam Gandía-Martínez14,
  30. José A Gómez-Puerta15,
  31. Consuelo Ramos-Giráldez16,
  32. Carmen Trapero-Pérez16,
  33. Elvira Díez-Álvarez17,
  34. Clara Moriano17,
  35. Alejandro Muñoz-Jiménez18 and
  36. Íñigo Rúa-Figueroa2
  1. 1Rheumatology, Complejo Hospitalario universitario de Vigo, Spain
  2. 2Rheumatology, Hospital Universitario De Gran Canaria Dr. Negrín, Spain
  3. 3Rheumatology, Hospital Universitario Germans Trias i Pujol, Spain
  4. 4Rheumatology, Hospital Universitario y Politécnico De La Fe, Spain
  5. 5Rheumatology, Hospital 12 De Octubre, Spain
  6. 6Rheumatology, Hospital Del Mar, Spain
  7. 7Rheumatology, Hospital Universitario De Bellvitge, Spain
  8. 8Rheumatology, Hospital Universitario Ramón y Cajal, Spain
  9. 9Rheumatology, Hospital Virgen Ae La Arrixaca De Murcia, Spain
  10. 10Rheumatology, Hospital General Universitario Gregorio Marañón, Spain
  11. 11Rheumatology, Hospital Universitario Valle d´ Hebrón, Spain
  12. 12Rheumatology, Hospital Universitario Araba, Spain
  13. 13Rheumatology, Hospital Universitario De La Princesa, Spain
  14. 14Rheumatology, Hospital Universitario De Jerez, Spain
  15. 15Rheumatology, Hospital Clinic De Barcelona, Spain
  16. 16Rheumatology, Hospital Universitario Nuestra Señora de Valme, Spain
  17. 17Rheumatology, Hospital Universitario De León, Spain
  18. 18Rheumatology, Hospital universitario Virgen Del Rocío, Spain
  19. 19Rheumatology, IRIDIS Group, Spain


Background Baseline profile of systemic lupus erythematosus patients on treatment with Belimumab of a Spanish multicenter cohort.

Methods Multicenter retrospective and longitudinal cohort study. Data was collected at baseline, 6, 12 months and in the last visit available. Different periods (2010–2015/2016–2021) were compared.

Results 324 patients (91% female) were enrolled. Mean (±SD) age at diagnosis: 31.8 years (±11.9); mean disease duration of 8.7 years (±9.07). At baseline, mean SLEDAI-2K score was 10.4 (±5.25); 152 (47.5%) patients had damage with a mean SDI score of 0.83 (±1.2). 289 patients (89.2%) had received DMARDs before BLM: cDMARDS in 282 (87%) and bDMARDs in 74 patients (22.8%); 164 (51.9%) had received more than one cDMARDs, methotrexate being the most frequently used (44.4%) and Rituximab the most frequent bDMARDs used (80%). Antimalarials were used in 83,2% and glucocorticoids (GC) in 91.2%, with a mean dose of 12.3 mg/day. 67.9% of patients were receiving more than 5 mg/day and 58.4% more than 7.5 mg/day of prednisone. BLM was used in monotherapy in 30.5% of subjects. Reasons of prescription: disease activity in 95% of patients and/or as a GC sparing agent in 59%. Only a few patients received BLM just for maintenance (4/322) or save GC (8/322). At baseline, 6 patients (1.9%) were in DORIS-21-remission and LLDAS. The main reasons of prescription for ongoing activity were arthritis (65.4%), cutaneous (40.7%) or both (81%). No differences were observed in prescription reasons between periods.

Conclusions Belimumab was mainly prescribed after the use of other DMARDs and more than 50% had received at least 2 DMARDs and were receiving GC at medium doses. Most patients received BLM due to active disease and/or as GC sparing agent. Activity in articular and cutaneous domains were the main reasons of indication. No changes in prescription habits were identified.

  • SLE
  • Rheumatology
  • Lupus

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.